| Style | Citing Format |
|---|---|
| MLA | Letafati A, et al.. "Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025." Health Science Reports, vol. 9, no. 8, 2026, pp. -. |
| APA | Letafati A, Marvi S S, Hosori N A, Molaverdi G, Esfandiari A, Moghadam N A, Siavoshi S, Norouzi M, Mozhgani S H (2026). Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025. Health Science Reports, 9(8), -. |
| Chicago | Letafati A, Marvi S S, Hosori N A, Molaverdi G, Esfandiari A, Moghadam N A, Siavoshi S, Norouzi M, Mozhgani S H. "Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025." Health Science Reports 9, no. 8 (2026): -. |
| Harvard | Letafati A et al. (2026) 'Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025', Health Science Reports, 9(8), pp. -. |
| Vancouver | Letafati A, Marvi S S, Hosori N A, Molaverdi G, Esfandiari A, Moghadam N A, et al.. Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025. Health Science Reports. 2026;9(8):-. |
| BibTex | @article{ author = {Letafati A and Marvi S S and Hosori N A and Molaverdi G and Esfandiari A and Moghadam N A and Siavoshi S and Norouzi M and Mozhgani S H}, title = {Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025}, journal = {Health Science Reports}, volume = {9}, number = {8}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Letafati A AU - Marvi S S AU - Hosori N A AU - Molaverdi G AU - Esfandiari A AU - Moghadam N A AU - Siavoshi S AU - Norouzi M AU - Mozhgani S H TI - Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (Htlv-1) in a Hospital Triage Population in Tehran During 2024–2025 JO - Health Science Reports VL - 9 IS - 8 SP - EP - PY - 2026 ER - |